Hereditary cancer accounts for nearly 5-10% of all cancers. With early detection through appropriate screening methods and prophylactic measures, the chances of prevention and successful treatment are higher.

The integration of cancer genetics in clinical practice enables physicians to distinguish a proportion of patients that have inherited mutations with increased risk susceptibility to certain cancers. The identification of such germline mutations allows for targeted cancer surveillance and prevention.

PreSENTIA, with an extensive portfolio of 19 hereditary cancer panels, tests for numerous inherited genetic mutations that could cause cancer in the future.

WHAT IS PreSENTIA?

PreSENTIA consists of an extensive portfolio of 19 hereditary cancer panels. The genes selected have been shown to predispose to certain hereditary cancer syndromes (cancer predisposition syndromes), and hereditary cancers.

The patients’ medical family history, their ethnicity, and any physical findings present linked to cancer should always be taken into consideration.

PreSENTIA offers 18 cancer-specific gene panels, and 1 hereditary pan-cancer panel that covers 62 genes and 24 cancer predisposing syndromes associated with hereditary cancer.

PreSENTIA is a new generation test for identifying genetic mutations with cancer susceptibility. It has an extensive portfolio of 19 hereditary cancer panels. Each panel focuses on a specific set of genes that have high susceptibility to cancer predisposing syndromes, that in turn have increased risk of causing cancer.

BENEFITS OF PreSENTIA INCLUDE:

  • Clinically actionable mutations
  • Proven technology
  • Easy-to-interpret results
  • Short turn-around time

The same mutation can cause cancer earlier in some family members than others, or not develop into cancer at all.

WHO IS THIS TEST FOR?

According to genetic testing guidelines* for cancer, people who might benefit from genetic testing are those that have:

  • Family members with cancer in the same side of the family
  • Multiple cancers in the same family member
  • Family members with early cancer onset
  • Family members with rare cancer types
  • A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
  • Personal or family history of a hereditary cancer syndrome

The patients’ medical family history, their ethnicity, and any physical findings present linked to cancer should always be taken into consideration.

Additionally, patients already diagnosed with cancer can take PreSENTIA if their family history is suggestive of an inherited genetic change running in their family. PreSENTIA can let them know if their cancer is hereditary, which will help to:

  • Improve disease classification
  • Inform other family members of their risk
  • Enhance clinical management

* Data adapted from: American Cancer Society, National Cancer Institute, American Society of Clinical Oncology and American College of Obstetricians and Gynecologists.

UNIQUE FEATURES

TARGETED TECHNOLOGY

PreSENTIA is based on a novel, target capture enrichment technology that has been validated for its accuracy and precision.

HIGH READ DEPTH

Specifically-designed genetic and bioinformatics methods have been incorporated to ensure high read-depths, raising the sensitivity and specificity of the test.

MULTI-ENGINE ANALYSIS

Proprietary bioinformatics pipelines analyze the sequencing data produced from each sample, increasing the sensitivity and specificity of PreSENTIA

WHY RECOMMEND PreSENTIA TO MY PATIENTS?

Identifying the genetic mutations that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning and avoiding risk factors.

WHAT ARE THE BENEFITS FOR MY PATIENTS?

  • Ability to select a panel that is most suited to them
  • Targeted cancer monitoring to detect cancer early, when treatment is more beneficial
  • Prevention of cancer by prophylactic measures
  • Invaluable information for family members that might carry the same mutation
  • Improved clinical care

HOW DOES PreSENTIA HELP ME?

PreSENTIA gives you helpful insight into the genetic makeup of your patient in an efficient, rapid and comprehensive way.

Receiving information about your patient's risk of developing cancer early allows you to look into the most appropriate prophylactic measures and therapy options.

You can develop a better clinical management plan for your patient and any of their family members who might also be affected.

WHAT CAN I DO TO HELP MY PATIENTS AFTER TAKING PreSENTIA?

  • Recommend screening tests at key interval timepoints for early cancer detection
  • Recommend prophylactic measures
  • Recommend testing for immediate family members who might be at risk

WHAT DOES IT TEST FOR?

HEREDITARY CANCER PANELS

  • BREAST & GYNECOLO­GICAL

    26

    HEREDITARY BREAST/GYNECOLOGICAL CANCER PANEL

    Description

    Hereditary Breast/Gynecological cancer panel tests for numerous germline mutations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for breast/gynaecological cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member with multiple cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • Personal history of previous malignancies

    No of Genes Tested

    26

    No of related hereditary cancer syndromes

    12

    Genes Tested

    ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • DICER 1 syndrome (DICER1)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, BRIP, MRE11, NBN, PALB2, RAD50, RAD51C, RAD51D, SMARCA4

  • BREAST / GYN GUIDELINES - BASED

    19

    HEREDITARY BREAST/GYNECOLOGICAL GUIDELINES-BASED CANCER PANEL

    Description

    Hereditary Breast/Gynecological cancer guidelines-based panel tests for numerous germline mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    19

    No of related hereditary cancer syndromes

    9

    Genes Tested

    ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, STK11

    Disorders associated with this panel:

    • Ataxia telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Peutz-Jeghers syndrome (STK11)
    • PTEN Hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, BRIP, NBN, PALB2, RAD51C, RAD51D

  • BREAST
    HIGH-RISK

    7

    HEREDITARY BREAST HIGH-RISK CANCER PANEL

    Description

    Hereditary Breast High-Risk cancer panel tests for numerous germline mutations that are associated with a high risk for developing Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53

    Disorders associated with this panel:

    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Peutz-Jeughers syndrome (STK11)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    PALB2

  • BRCA1 / BRCA2

    2

    HEREDITARY BRCA1 / BRCA2 CANCER PANEL

    Description

    Hereditary BRCA1/BRCA2 cancer panel tests for germline mutations in the BRCA1 and BRCA2 genes that could cause specific cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers caused by mutations in the BRCA1/BRCA2 genes are those that have:

    • Several family members with cancer in the same side of the family
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    2

    No of related hereditary cancer syndromes

    1

    Genes Tested

    BRCA1, BRCA2

    Disorders associated with this panel:

    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)

  • COLORECTAL

    17

    HEREDITARY COLORECTAL CANCER PANEL

    Description

    Hereditary Colorectal cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • Personal history of previous malignancies

    No of Genes Tested

    17

    No of related hereditary cancer syndromes

    12

    Genes Tested

    APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • PTEN Hamartoma syndrome (PTEN)
    • Peutz-Jeghers syndrome (STK11)
    • Hereditary diffuse gastric syndrome (CDH1)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
    • Polymerase Proofreading Associated syndrome (POLD1, POLE)
    • Hereditary mixed polyposis syndrome (GREM1)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A)
    • Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2)

  • COLORECTAL
    HIGH-RISK

    10

    HEREDITARY COLORECTAL HIGH-RISK CANCER PANEL

    Description

    Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    10

    No of related hereditary cancer syndromes

    6

    Genes Tested

    APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11

    Disorders associated with this panel:

    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)

  • COLORECTAL
    NON-POLYPOSIS

    5

    HEREDITARY COLORECTAL NON-POLYPOSIS CANCER PANEL

    Description

    Hereditary Colorectal Non-Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    5

    No of related hereditary cancer syndromes

    2

    Genes Tested

    EPCAM, MLH1, MSH2, MSH6, PMS2

    Disorders associated with this panel:

    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

  • COLORECTAL POLYPOSIS SYNDROME

    7

    HEREDITARY COLORECTAL POLYPOSIS CANCER PANEL

    Description

    Hereditary Colorectal Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary polyposis colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    APC, BMPR1A, MUTYH, POLD1, POLE, SMAD4,STK11

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)

  • MYELODYSPLASTIC SYNDROME/LEUKEMIA

    24

    HEREDITARY MYELODYSPLASTIC SYNDROME / LEUKEMIA CANCER PANEL

    Description

    Hereditary Myelodysplastic syndrome / Leukemia cancer panel tests for numerous germline mutations that could cause blood cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukemias are those that have:

    • Family history of a hereditary cancer syndrome associated with leukemia
    • Personal history of a hereditary cancer syndrome associated with leukemia
    • An identical twin who developed leukemia in the first year of life
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    24

    No of related hereditary cancer syndromes

    6

    Genes Tested

    ATM, BRCA1, BRCA2, BRIP1, EPCAM, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, SLX4, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
    • Hereditary breast & ovarian syndrome (BRCA1 & BRCA2)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

  • GASTRIC

    14

    HEREDITARY GASTRIC CANCER PANEL

    Description

    Hereditary Gastric cancer panel tests for numerous inherited germline mutations that could cause gastric (stomach) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for gastric cancers are those that have:

    • Several family members in the same side of the family with gastric cancer
    • Personal or family history of a hereditary cancer syndrome linked to gastric cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    14

    No of related hereditary cancer syndromes

    8

    Genes Tested

    APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Hereditary Paraganglioma-Pheochromocytoma syndrome (SDHB, SDHC, SDHD)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Peutz-Jeghers syndrome (STK11)

  • PROSTATE

    15

    HEREDITARY PROSTATE CANCER PANEL

    Description

    Hereditary Prostate cancer panel tests for numerous germline mutations that could cause prostate cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • Several first-degree family members with prostate cancer
    • Family members diagnosed with prostate cancer at young age
    • Family members diagnosed with other cancer types, including breast, ovarian and pancreatic
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    15

    No of related hereditary cancer syndromes

    6

    Genes Tested

    ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    HOXB13, NBN, PALB2, RAD51D

  • PANCREATIC

    17

    HEREDITARY PANCREATIC CANCER PANEL

    Description

    Hereditary Pancreatic cancer panel tests for numerous germline mutations that could cause pancreatic cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for pancreatic cancers are those that have:

    • Several family members in the same side of the family with pancreatic cancer
    • First-degree relative who developed pancreatic cancer before the age of 50
    • Personal or family history of a hereditary cancer syndrome linked to pancreatic cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    17

    No of related hereditary cancer syndromes

    10

    Genes Tested

    APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), EPCAM, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Multiple endocrine neoplasia type 1 (MEN1)
    • Peutz-Jeghers syndrome (STK11)

  • RENAL

    13

    HEREDITARY RENAL CANCER PANEL

    Description

    Hereditary Renal cancer panel tests for numerous germline mutations that could cause renal (kidney) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary renal cancers are those that have:

    • Family members that have had renal cancer, especially at a young age
    • Family members with renal cancer in both kidneys
    • Family members diagnosed with a hereditary cancer syndrome associated with renal cancer
    • Personal history of a hereditary cancer syndrome associated with renal cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    13

    No of related hereditary cancer syndromes

    7

    Genes Tested

    BAP1, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, SDHAF2, SDHB, SDHC, SDHD, TP53, VHL

    Disorders associated with this panel:

    • BAP1 mutation associated disease (BAP1)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHC, SDHD)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • PTEN hamartoma syndrome (PTEN)
    • Von-Hippel Lindau syndrome (VHL)

  • SKIN (XP-ASSOCIATED)

    9

    HEREDITARY SKIN (XP-ASSOCIATED) CANCER PANEL

    Description

    Hereditary Xeroderma Pigmentosum-related cancer panel tests for numerous germline mutations that could cause skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for Xeroderma Pigmentosum-related skin cancers are those that have:

    • Family or personal history of a hereditary cancer syndrome associated with skin cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    9

    No of related hereditary cancer syndromes

    1

    Genes Tested

    DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC

    Disorders associated with this panel:

    • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

  • FAMILIAL MELANOMA

    7

    HEREDITARY FAMILIAL MELANOMA CANCER PANEL

    Description

    Hereditary Familial Melanoma cancer panel tests for numerous germline mutations that could cause familial melanoma skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary melanoma cancers are those that have:

    • At least two first-degree family member who have had metastatic melanoma
    • At least one family member has had multiple melanomas
    • Family or personal history of a hereditary cancer syndrome associated with melanoma
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    BAP1, BRCA2, CDK4, CDKN2A (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), PTEN, RB1, TP53

    Disorders associated with this panel:

    • BAP1 mutation associated disease (BAP1)
    • Hereditary pancreatic-melanoma syndrome (CDKN2A, CDK4)
    • Li-Fraumeni syndrome (TP53)
    • PTEN hamartoma syndrome (PTEN)
    • Retinoblastoma (RB1)

  • PARAGANGLI­OMA / PHEOCHROMOCYTOMA

    6

    HEREDITARY PARAGANGLIOMA / PHEOCHROMOCYTOMA CANCER PANEL

    Description

    Hereditary Paraganglioma / Pheochromocytoma cancer panel tests for germline mutations in numerous genes that could cause Paraganglioma or Pheochromocytoma cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for Paraganglioma or Pheochromocytoma cancers are those that have:

    • Family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    6

    No of related hereditary cancer syndromes

    3

    Genes Tested

    RET, SDHAF2, SDHB, SDHC, SDHD, VHL

    Disorders associated with this panel:

    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHD, SDHC)
    • Multiple endocrine neoplasia type 2 (RET)
    • Von-Hippel Lindau syndrome (VHL)

  • PARATHYROID

    1

    HEREDITARY PARATHYROID CANCER PANEL

    Description

    Hereditary Parathyroid cancer panel tests for germline mutations in the MEN1 gene that could cause parathyroid cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

    • At least two first-degree family member who have had parathyroid tumors
    • A personal or family history of a hereditary cancer syndrome associated with parathyroid cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    1

    No of related hereditary cancer syndromes

    1

    Genes Tested

    MEN1

    Disorders associated with this panel:

    • Multiple endocrine neoplasia type 1 (MEN1)

  • THYROID

    1

    HEREDITARY THYROID CANCER PANEL

    Description

    Hereditary Thyroid cancer panel tests for germline mutations in the RET gene that could cause medullary thyroid cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

    • At least one first-degree family member who has had thyroid cancer
    • A personal or family history of a hereditary cancer syndrome associated with thyroid cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    1

    No of related hereditary cancer syndromes

    1

    Genes Tested

    RET

    Disorders associated with this panel:

    • Multiple endocrine neoplasia type 2 (RET)

  • PAN-CANCER

    62

    HEREDITARY PAN-CANCER PANEL

    Description

    Hereditary Pan-Cancer panel tests for numerous germline mutations in a total of 62 genes that could cause several cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • Family members with an unusual type of cancer (breast cancer in a male)
    • Personal or family history of a hereditary cancer syndrome
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    62

    No of related hereditary cancer syndromes

    24

    Genes Tested

    APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), CHEK2, DDB2, DICER1, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GREM1, HOXB13, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, POLH, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, STK11, TP53, VHL, XPA, XPC

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • BAP1 mutation associated disease (BAP1)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • DICER 1 syndrome (DICER1)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Hereditary mixed polyposis syndrome (GREM1)
    • Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Multiple endocrine neoplasia type 1 (MEN1)
    • Multiple endocrine neoplasia type 2 (RET)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)
    • PTEN hamartoma syndrome (PTEN)
    • Retinoblastoma (RB1)
    • Von-Hippel Lindau syndrome (VHL)
    • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, MRE11, RAD50, SMARCA4, HOXB13, NBN, RAD51D

  • HEREDITARY CANCER SYNDROMES

    AD= Autosomal Dominant, AR= Autosomal Recessive, XLR= X-Linked Recessive

    Cancer Predisposing Syndromes & Associated Genes Associated Cancers PreSENTIA Hereditary Cancer Panel
    Li-Fraumeni syndrome (AD)
    TP53
    Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain, Lung, Leukemia
    • 3 Breast / Gynecological Cancer Panels
    • Colorectal Cancer Panel
    • Gastric Cancer Panel
    • Familial Melanoma Cancer Panel
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pancreatic Cancer Panel
    • Prostate Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    Li-Fraumeni syndrome 2 (AD)
    CHEK2
    Breast, Sarcoma, Brain
    • 2 Breast / Gynecological Cancer Panels
    • Colorectal Cancer Panel
    • Prostate Cancer Panel
    • Pan-Cancer Panel
    Hereditary breast and ovarian cancer syndrome (AD)
    BRCA1, BRCA2
    Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus
    • 4 Breast / Gynecological Cancer Panels
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pancreatic Cancer Panel
    • Prostate Cancer Panel
    • Pan-Cancer Panel
    Familial adenomatous polyposis / Attenuated familial adenomatous polyposis syndrome (AD)
    APC
    Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel
    • 3 Colorectal Cancer Panels
    • Gastric Cancer Panel
    • Pancreatic Cancer Panel
    • Pan-Cancer Panel
    MUTYH-associated polyposis syndrome (AR)
    MUTYH
    Colorectal
    • Breast / Gynecological Cancer Panel
    • 3 Colorectal Cancer Panels
    • Pan-Cancer Panel
    Lynch syndrome (AD)
    MLH1, MSH2, MSH6, PMS2, EPCAM
    Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal
    • 2 Breast / Gynecological Cancer Panels
    • 3 Colorectal Cancer Panels
    • Gastric Cancer Panel
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pancreatic Cancer Panel
    • Prostate Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    PTEN hamartoma syndrome (AD)
    PTEN
    Breast, Endometrial, Colorectal, Melanoma, Renal
    • 3 Breast / Gynecological Cancer Panels
    • Colorectal Cancer Panel
    • Familial Melanoma Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    Peutz-Jeghers syndrome (AD)
    STK11
    Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic
    • 3 Breast / Gynecological Cancer Panels
    • 3 Colorectal Cancer Panels
    • Gastric Cancer Panel
    • Pancreatic Cancer Panel
    • Pan-Cancer Panel
    Juvenile polyposis syndrome (AD)
    SMAD4, BMPR1A
    Colorectal, Gastric, Pancreatic
    • 3 Colorectal Cancer Panel
    • Gastric Cancer Panel
    • Pancreatic Cancer Panel
    • Pan-Cancer Panel
    Fanconi anemia syndrome (AR or XLR)
    FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C
    Leukemia, Tumors of the head & neck, Gastrointestinal
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pan-Cancer Panel
    Von-Hippel Lindau syndrome (AD)
    VHL
    Renal, Paragangliomas, Pheochromocytomas
    • Paraganglioma / Pheochromocytoma Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    Retinoblastoma (AD)
    RB1
    Eye & bone
    • Familial Melanoma Cancer Panel
    • Pan-Cancer Panel
    Xeroderma Pigmentosum syndrome (AR)
    DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA,XPC
    Non-Melanoma & Melanoma
    • Skin (XP-associated) Cancer Panel
    • Pan-Cancer Panel
    Hereditary melanoma-pancreatic cancer (AD)
    CDKN2A, CDK4
    Melanoma, Pancreatic
    • Familial Melanoma Cancer Panel
    • Pancreatic Cancer Panel
    • Pan-Cancer Panel
    Hereditary diffuse gastric syndrome (AD)
    CDH1
    Gastric & Breast
    • 3 Breast / Gynecological Cancer Panels
    • Colorectal Cancer Panel
    • Gastric Cancer Panel
    • Pan-Cancer Panel
    DICER 1 syndrome (AD)
    DICER1
    Lung, Renal, Ovarian, Thyroid
    • Breast / Gynecological Cancer Panel
    • Pan-Cancer Panel
    Polymerase Proofreading Associated syndrome (AD)
    POLD1, POLE
    Colorectal & Endometrial
    • Breast / Gynecological Cancer Panel
    • 2 Colorectal Cancer Panels
    • Pan-Cancer Panel
    Multiple Endocrine Neoplasia (MEN) syndrome type 1 (AD)
    MEN1
    Parathyroid & Pancreatic
    • Pancreatic Cancer Panel
    • Parathyroid Cancer Panel
    • Pan-Cancer Panel
    Multiple Endocrine Neoplasia (MEN) syndrome type 2 (AD)
    RET
    Thyroid & Pheochromocytoma
    • Paraganglioma / Pheochromocytoma Cancer Panel
    • Thyroid Cancer Panel
    • Pan-Cancer Panel
    BAP1 mutation associated disease (AD)
    BAP1
    Skin, Eye, Renal, Mesothelioma
    • Familial Melanoma Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel
    Ataxia-telangiectasia syndrome (AR)
    ATM
    (Susceptibility to breast, pancreatic & prostate cancer: AD)
    Leukemia & Lymphoma
    • 2 Breast / Gynecological Cancer Panels
    • Pancreatic Cancer Panel
    • Prostate Cancer Panel
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Pan-Cancer Panel
    Hereditary-mixed polyposis syndrome (AR)
    GREM1
    Colorectal
    • Colorectal Cancer Panel
    • Pan-Cancer Panel
    Constitutional mismatch repair syndrome (AR)
    MSH2, MSH6, MLH1, PMS2
    Hematologic malignancies, Brain, Gastrointestinal, Colorectal
    • 2 Breast / Gynecological Cancer Panels
    • 3 Colorectal Cancer Panels
    • Myelodysplastic syndrome / Leukemia Cancer Panel
    • Gastric Cancer Panel
    • Pancreatic Cancer Panel
    • Renal Cancer Pane
    • Pan-Cancer Panel
    Hereditary Paraganglioma – Pheochromocytoma syndrome (AD)
    SDHAF2, SDHB, SDHC, SDHD
    Renal, Thyroid, Paragangliomas, Pheochromocytomas
    • Paraganglioma / Pheochromocytoma Cancer Panel
    • Renal Cancer Panel
    • Pan-Cancer Panel

HOW TO ADMINISTER PreSENTIA?

  • RECOMMEND THE IDEAL PANEL TO YOUR PATIENT
  • COLLECT A BUCCAL SWAB FROM YOUR PATIENT
  • SEND THE SAMPLE TO OUR LABORATORY
  • THE SAMPLE WILL BE ANALYZED IN OUR LABORATORY
  • RESULTS WILL BE SENT TO YOU WITHIN 2-3 WEEKS

NIPD Genetics - Privacy Policy

General Statement

NIPD Genetics is a leading, innovative biotechnology company that designs, develops, and provides a broad spectrum of healthcare services to its customers through its expansive portfolio of molecular and clinical laboratory tests in all disciplines.

At NIPD Genetics we are committed to protecting and respecting our customer’s privacy and personal information. Personal information or personal data means any information that identifies, relates to, describes, is capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular individual, such as name, identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that individual.

NIPD Genetics collects and processes your personal information according to the General Data Protection Regulation (EU) 2016/679 and the Cypriot law providing for the protection of natural persons with regards to the processing of personal data and for the free movement of such data (L. 125(I)/2018). The following principles lie at the heart of our approach to handling personal data:

NIPD Genetics has appointed a Data Protection Officer (DPO) who is responsible for overseeing and ensuring that personal information is collected and processed in line with these principles. The contact details of the Data Protection Officer (DPO) can be found below:

Email address: dpo@nipd.com

Postal address: 31 Neas Engomis street, 2409 Engomi, Nicosia, Cyprus

Telephone number: + 357 22266888

By accessing or using our products or services, or by transmitting information to us by email or other electronic means, you accept our policies, procedures and practices described in this Privacy Policy. If you do not agree with our policies, procedures and practices as described, you can choose not to access or use our products or services or not to transmit personal information to us.

This Privacy Policy applies to NIPD Genetics facilities, its websites www.nipd.com, www.nipdlabs.com, www.nipdlabs.com.cy and their subdomains, that link to this privacy pol icy.

PERSONAL INFORMATION COLLECTION AND PROCESSING

We collect and process several types of personal information from and about users of our websites and of our products and services, including:

Information about children

If you are under 18 years of age, do not register on our website or provide any information about yourself to us. We do not provide our products or services directly to children or proactively collect their personal information. Despite this prohibition, it is possible that we may sometimes be given information about children while handling samples from our customers in our clinical labs, or through use of our products and services by our customers and partners. If we become aware that we have inadvertently collected personal information from children under the age of 18, without parental consent, we will take the necessary steps to delete it as soon as possible in compliance with applicable laws.

LEGAL BASIS FOR PROCESSING OF YOUR PERSONAL INFORMATION

Your personal information is collected by NIPD Genetics for the following purposes:

  1. To provide you with our products and services, respond to your inquiries or fulfill your requests and otherwise manage your relationship with us. The legal basis for processing is to meet the requirements of a contract, to comply with our legal obligations and/or because we have a legitimate interest in responding to requests for information about our products and services.
  2. To communicate with you about content and product offerings, newsletters and event invitations which are relevant to your interests and in line with your preferences. The legal basis for processing is the individual’s explicit consent prior to sending the information and managing individuals preferences.
  3. To process and respond to complaints. The legal basis for processing is to meet a legal obligation.
  4. To monitor and record information relating to the use of our products and services, including our website. The legal basis for processing is our legitimate interest in order to improve our products and services and our website for individuals.

To provide our products and services, NIPD Genetics may collect, receive and process biological samples to isolate and sequence DNA. NIPD Genetics may then store resulting genetic information and use genetic information to provide our products and services. In some cases, NIPD Genetics may provide interpretations of genetic information on behalf of its customers, including healthcare providers. This is only done pursuant to a written contract or a Sample Information Form with a patient’s informed consent and is subject to applicable legal and ethical safeguards.

This sensitive information described above is collected by NIPD Genetics for the following purposes:

  1. To provide support and maintenance services to customers who use our products and services – The legal basis for processing is to meet the requirements of a contract.
  2. To provide genotyping and sequencing services and analysis for our customers, including healthcare providers. The legal basis of this processing is to meet the requirements of a contract or as allowed in the Sample Information Form with a patient’s informed consent.
  3. To conduct genotyping and sequencing services and analysis for quality control, process and product development and improvements, and optimization in our labs to reflect quality improvements and advances in our technology. The legal basis for processing is the patient’s informed consent given through the Sample Information Form.

Transfer of Data

Your information, including personal data, may be transferred to - and maintained on - computers located outside your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

NIPD Genetics will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal information will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the General Data Protection Regulation and will not sell or trade your personal information.

NIPD Genetics may disclose your personal information in the good faith that such action is necessary:

COOKIES AND OTHER TRACKING TECHNOLOGIES

Cookies are files with small amount of data which may include an anonymous unique identifiers. Cookies are sent to your browser when you visit a website and stored on your device. Tracking technologies used on the website are beacons, tags and scripts, to collect and track information and to improve and analyze our websites.

We use cookies and similar tracking technologies to track the activity on our websites and collect certain information. This includes information about the computer or device you are using, such as Internet protocol (IP) address, information about the browser type or version, the pages of our website that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our websites.

Examples of Cookies we may use:

Session Cookies. We use Session Cookies to operate our websites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the websites

Keyword cookies. To understand how visitors discover the websites.

ANALYTICS

We may use third-party Service Providers to monitor and analyze the use of our websites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

SECURITY OF DATA

We are committed to protecting the security of the information we collect, and we take reasonable physical, technical, and administrative safeguards such as data anonymization and encryption to help protect personal information from unauthorized or inappropriate access or use. It is your responsibility to protect the confidentiality of your passwords, and any other access features associated with your access or use of the website or our products and services, as well as to adhere to any applicable Terms of Use or other contract between us and you or your organization.

PERSONAL DATA RETENTION

We may retain collected information even after you remove it from the website, our Services, or our Products, to comply with applicable law, to resolve disputes, to enforce any rights in connection with the website, our Services, or our Products, and to use as provided in this Privacy Policy, the Terms of Use, or an applicable contract between us and you or your organization. How long we retain specific personal information varies depending on the purpose for its use and we may delete or retain your personal information in accordance with applicable law.

SERVICE PROVIDERS

We may employ third party companies and individuals to facilitate, maintain or operate our websites (“Service Providers”), to provide the websites on our behalf, to perform service-related services or to assist us in analyzing how our websites are used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

LINKS TO OTHER SITES

Our websites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

CHANGES TO THIS PRIVACY POLICY

This Privacy Policy may be updated from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our website, prior to the change becoming effective and update the “effective date” at the bottom of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

YOUR LEGAL RIGHTS

NIPD Genetics ensures that it can respond immediately to requests that you make for the exercise of your legal rights in accordance with data protection laws. These rights are as follows:

You also have the right to lodge a complaint at any time to the Office of the Commissioner for Personal Data Protection.

We encourage you to contact us, should you wish to practice any of your legal rights or you have any questions about this Privacy Policy, by sending an email to NIPD Genetics’ Data Protection Officer at dpo@nipd.com.

Effective date: 18/06/2021

Ok got it!